Company intelligence / Profile preview

PrimeGene

Shanghai, Shanghai, Chinaprimegene.com ↗

Ownership: Private
Development stage: Phase 2

Overview

PrimeGene supplies over 600 recombinant protein products across more than twenty species. The company has established GMP-grade production capabilities and serves both scientific research and industrial customers worldwide. It was acquired by Bio-Techne in April 2014. No clinical trial results as it does not develop drugs directly.

Therapeutic areas: Other
Modalities: Recombinant proteins (including cytokines, growth factors, enzymes)GMP-grade proteins for cell therapy and biopharma applications
Industry: Chemicals & Materials

Drug pipeline

1 asset

pemetrexedinib

Phase 2

Indications: Atopic dermatitis, Seasonal allergic rhinitis

Partnerships

Parent company integration with Bio-Techne expands global reach and product portfolio synergy.

Beyond the preview

Go deeper on PrimeGene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PrimeGene.

Explore the full profile